Literature DB >> 7150874

The effect of chlorpromazine, metyrapone, imipramine and SKF 525-A on the hepatic first pass elimination of propranolol in the pithed rat.

H E Barber, N R Kitteringham, J C Petrie.   

Abstract

1 The effect of chlorpromazine, metyrapone, imipramine and SKF 525-A on the hepatic first pass elimination of propranolol has been studied in the pithed rat. 2 The effect of chlorpromazine, metyrapone, imipramine and SKF 525-A on the inhibition caused by propranolol of an elicited electrically induced tachycardia has also been studied. 3 The hepatic first pass elimination of propranolol was reduced following pretreatment with chlorpromazine, imipramine and SKF 525-A but was not affected by pretreatment with metyrapone. 4 Chlorpromazine, imipramine and SKF 525-A all resulted in an increased propranolol blood concentration after hepatic portal vein administration which was associated with decreased formation of metabolites and an enhanced inhibition of an electrically induced tachycardia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7150874      PMCID: PMC2044668          DOI: 10.1111/j.1476-5381.1982.tb09345.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Inhibitory effects of beta-diethylaminoethyl diphenylpropylacetate on a variety of drug metabolic pathways in vitro.

Authors:  J R COOPER; J AXELROD; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1954-09       Impact factor: 4.030

2.  Effects of alteration of hepatic microsomal enzyme activity on liver blood flow in the rat.

Authors:  A S Nies; G R Wilkinson; B D Rush; J R Strother; D G McDevitt
Journal:  Biochem Pharmacol       Date:  1976-09-01       Impact factor: 5.858

3.  Inhibition of propranolol metabolism by chlorpromazine.

Authors:  R E Vestal; D M Kornhauser; J W Hollifield; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

4.  Chlorpromazine inhibition of p-aminophenol glucuronidation by rat hepatoma cells in culture.

Authors:  E Dybing
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1972

5.  The possible role of cytochrome P-450 in the liver "first pass elimination" of a beta-receptor blocking drug.

Authors:  R Grundin; P Moldéus; S Orrenius; K O Borg; I Skånberg; C von Bahr
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-09

6.  The disposition of propranolol. II. Hepatic elimination in the rat.

Authors:  D G Shand; R E Rangno; G H Evans
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

7.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

8.  Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients.

Authors:  M Peet; D N Middlemiss; R A Yates
Journal:  Lancet       Date:  1980-11-01       Impact factor: 79.321

9.  Determination of propranolol and six metabolites in human urine by high-pressure liquid chromatography.

Authors:  J F Pritchard; D W Schneck; A H Hayes
Journal:  J Chromatogr       Date:  1979-01-01

10.  A method of stimulating different segments of the autonomic outflow from the spinal column to various organs in the pithed cat and rat.

Authors:  J S Gillespie; A Maclaren; D Pollock
Journal:  Br J Pharmacol       Date:  1970-10       Impact factor: 8.739

View more
  3 in total

1.  The effect of a single treatment with cigarette smoke on the blood levels and hemodynamic effects of propranolol in rats.

Authors:  T Berkan; L Ustünes; Z Kerry; M Karol; M Tosun; C Yalçinkaya; A Ozer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jul-Sep       Impact factor: 2.441

2.  Endothelium is required in the vascular spasm induced by tetraethylammonium and endothelin-1 in guinea-pig aorta.

Authors:  P Dorigo; I Maragno; G Santostasi; D Fraccarollo
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  Effects of chlorpromazine on the disposition and beta-adrenergic blocking activity of propranolol in the dog.

Authors:  S A Bai; F P Abramson
Journal:  J Pharmacokinet Biopharm       Date:  1984-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.